The present results revealed that two CaMKII inhibitors, KN-93 and acremomannolipin A, decreased fat mass, attenuated HFD-induced increases in epididymal and subcutaneous WAT weights, and ameliorated glucose intolerance without any obvious side effects in mice. Here, CAMK2G is linked to Glucose intolerance.